Augsburg University

Idun
Theses and Graduate Projects

2019

Cervical Cancer Screening and Prevention in
Central America
Madeline Jensen
Augsburg University

Follow this and additional works at: https://idun.augsburg.edu/etd
Part of the Women's Health Commons
Recommended Citation
Jensen, Madeline, "Cervical Cancer Screening and Prevention in Central America" (2019). Theses and Graduate Projects. 952.
https://idun.augsburg.edu/etd/952

This Open Access Thesis is brought to you for free and open access by Idun. It has been accepted for inclusion in Theses and Graduate Projects by an
authorized administrator of Idun. For more information, please contact bloomber@augsburg.edu.

Cervical Cancer Screening and Prevention in Central America
By
Madeline Jensen
Dr. Holly Levine

Paper Submitted in Partial Fulfillment
Of the Requirements for the Degree
Of Master of Science
Physician Assistant Studies
Augsburg University

Cervical Cancer 2
Table of Contents
Abstract…………………………………………………………. 3
Introduction…………………………………………………….. 3
Background……………………………………………….…….. 5
Methods………………………………………………………….13
Discussion………………………………………………………..13
Conclusion……………………………………………………….17
References……………………………………………….....…….19
Appendices……………………………………………………….21

Cervical Cancer 3
Abstract
Cervical cancer is the fourth most frequent cancer in women around the world. In the
Central American region, it is a leading cause of mortality for young women due to inadequate
preventive and screening measures. The disease is slow-growing and caused by the human
papillomavirus, which is transmitted via sexual contact. The HPV vaccination was created in
order to prevent the disease, and there are a variety of quality screening methods to quickly
identify progression. The most common screening methods include the Papanicolaou (Pap) test
and visualization by acetic acid (VIA). While frequent screening is common in developed
countries, rates are much lower in Central American countries primarily due to financial and
educational constraints. In order to prevent cases of cervical cancer in this region, current
educational assistance programs should be expanded, and financial assistance must be procured.
In terms of screening, VIA should be preferred over Pap testing in Central America due to its
cost effectiveness and lesser training requirements.
Introduction
According to the World Health Organization, cervical cancer is currently the fourth most
frequent cancer in women across the globe.1 In comparison to other malignancies, it is a slowgrowing disease, but it can be deadly if not caught and treated in a timely manner. In 2018, there
were approximately 311,000 women who lost their lives to the disease.2 Of these women, over
85% resided in a less-developed or middle-income country.1-2 In the Latin American region in
particular, cervical cancer is the most common cause of mortality due to malignant neoplasm in
women 20-40 years of age.3 These statistics are alarming, given that with adequate screening and
intervention methods, cervical cancer is a preventable and treatable disease.
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The vast majority of cervical cancer is caused by infection of the human papillomavirus
(HPV), which is a group of non-enveloped double stranded DNA tumor viruses.4 HPV is the
most common sexually transmitted infection (STI), and can be spread during vaginal, anal, or
oral sex with an infected person, as well as through skin-to-skin genital contact.5 There are more
than 100 different types of HPV, but only a select few cause disease. As the virus infects the skin
and mucosa, some types can manifest as benign warts, whereas others will result in no symptoms
at all. It can take weeks, months, or even years after infection for warts to develop after the initial
infection.6 Persistent and untreated infection of types 6, 11, 16, and 18 have been identified to
cause nearly all cervical cancers in addition to some vaginal, vulvar, and anal cancers. 2,4 HPV
was not determined to be the essentially exclusive cause until the 1980’s, and the discovery has
allowed researchers to develop extremely effective preventative and screening recommendations
for the public as well as providers. Similar to warts, cancers can take years to develop after an
HPV infection. Around the world, annual cancer cases attributable to HPV number 570,000 in
women and 60,000 in men.7 Without effective screening methods, it is nearly impossible to
identify and treat these cancers in their earliest stages.
Because cervical cancer does not evolve as rapidly as some other cancers, the HPV
infection commonly follows a fairly predictive course. The progression begins with a sexually
transmitted HPV infection that occurs shortly after sexual activity. It is more common for a male
partner to pass the virus to a female partner, but transmission occurs both ways. Contracting
HPV is so common that researchers estimate that almost every person who is sexually active will
get HPV at some point if they are not vaccinated.5 In the majority of patients, the body clears the
virus without trouble, and there is no further disease progression. Two years after acquisition,
90% of infections will have cleared without any intervention.2 However, if the infection consists
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of one of the known carcinogenic strains, the abnormal cells are more likely to persist and grow.
It is clear that action should be taken in these cases, but there can be limitations to consider.
Depending on the region of the world, financial and geographical strains may prevent access to
healthcare. Patients in less-developed or lower income countries are much less likely to have
access to preventative care than if they resided in a developed country. In addition, there is a lack
of effective programs to raise awareness about HPV and to bring in proper training in many
Central American communities.
Ultimately, the prevalence of global HPV transmission identifies a prominent public
health issue that requires evaluation of screening and preventative measures. According to the
Centers for Disease Control and Prevention (CDC) in the United States, 93% of cervical cancers
could have been prevented with either vaccination or screening. 5 This identifies a prominent gap
in healthcare services for those in developing countries or without access to healthcare. The
countries within Central America are in varying stages of political, economic, and social
development and can provide insight into the challenges of implementing the ideal approaches.
As cervical cancer is the leading cause of cancerous mortality for women in this area, it is
imperative to find plausible ways to prevent these unnecessary deaths. This paper will explore
the current methods in Central America, and identify opportunities to implement further action.
Background
Cervical Cancer Progression
The cervix itself contains two types of cells. The endocervix is covered with glandular
cells, and the ectocervix contains squamous cells. Both cell types come together in an area of
metaplastic tissue between the endocervical canal and the vagina, called the transformation zone.
Although any epithelial tissue can be infected by HPV, the transformation zone is the most

Cervical Cancer 6
susceptible area for progression to precancers and cancers to occur. According to the American
Cancer Society, 90% of cervical cancers are squamous cell carcinomas, and the majority of the
others are adenocarcinomas from the glandular cells. 8
As previously mentioned, nearly all cervical cancers begin with a sexually-transmitted
HPV infection. While these infections are very common, there are some factors that can put a
patient at higher risk for STIs, including HPV. Having unprotected sex, sexual contact with
multiple partners, and abusing drugs and alcohol all put a person at higher risk for contracting an
STI. For HPV in particular, researchers have determined an increased risk in those who are
immunocompromised, have had other STIs, have had many children, have been on long term
oral contraceptives, and who engage in smoking tobacco. 2,9 Following a minority of cases of
infection, evidence of abnormal cellular morphology is detected. These findings are usually
labeled by laboratories as “atypical squamous cells of undetermined significance (ASC-US)” or
“low-grade squamous intraepithelial lesions (LSIL).” These abnormalities are transient, with
over 50% naturally clearing in one year, and 90% by two years.8
Unfortunately, cellular abnormalities can only be detected if the patient is seen in a
healthcare setting for a pelvic exam. If the abnormal cells are not identified and treated at this
point, there is a small chance that an unresolved low-grade lesion could progress to a high-grade
squamous intraepithelial lesion (HSIL). In these cases, further cellular changes may continue,
and there is potential for the abnormal morphology to fully develop into cervical cancer cells.
Though not all high-grade lesions will become cancerous, they are considered “pre-cancerous” in
nature. The majority of women with precancerous lesions will not display any symptoms of the
underlying disease. Cells are most likely to progress to malignancy if the initial HPV infection
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was high-risk, such as with HPV types 16 and 18.10 Cancer development occurs after cell
dysplasia has been ongoing for as many as 10-15 years.
When advanced dysplasia is allowed to advance without intervention, malignancy can
occur. At this point, the cancer can be classified as either a squamous cell carcinoma or an
adenocarcinoma. These early stages of cancer are when most women begin to experience
symptoms. Patients may notice irregular vaginal bleeding or abnormal vaginal discharge. As
with any cancer, cells can break away and travel through the bloodstream or the lymph system
and form new tumors. Nearby lymph nodes are usually affected first, but cancer can spread to the
vagina, bladder, rectum, and walls of the pelvis. At this stage, there is a 56% 5-year survival rate
for women.8 In later stages, the cancer has spread to distant lymph nodes, lungs, bones, or liver.
When metastatic disease is present, women may recognize changes in urination or defecation,
fatigue, and weight loss.9 The 5-year survival rate drops to 17% in these cases.8 The slowgrowing nature of cervical cancer allows for many opportunities to identify and treat the lesions
in their early stages. Women cannot rely on presenting symptoms to seek healthcare. At the time
of symptom presentation, the cancer may already be metastatic.
Global Recommendations for Prevention and Screening
Since the 1940s, the methods for screening and prevention of cervical cancer have
developed substantially. With better technology and methodology, rates of incidence and
mortality of cervical cancer have decreased dramatically. The first screening option created was
the Papanicolaou (Pap) test, which involves collecting cells from the transition zone of the cervix
and performing cytology to assess the morphology. Implementation of this method allows for
abnormal lesions to be caught and treated before they progress to symptomatic and dangerous
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cancers. The International Agency for Research on Cancer (IARC) found that the occurrence of
invasive cervical cancer could be reduced by 80% or more with Pap-based screening programs.11
The World Health Organization (WHO) recommends that women with positive cytology results
(ASCUS, LSIL, HSIL) should either repeat cytology in a year or undergo further testing such as
HPV testing, colposcopy, and biopsy to further characterize the lesions. 12 Alternatively, women
who test negative on cytology (Pap) should be routinely screened every three to five years. 12
While the Pap test is widely used, the results must be examined under microscopy, and there is
potential for human error.
While not as widely recommended in developed countries, another screening technique
frequently used is visual inspection by acetic acid (VIA). This is an inexpensive test in which
acetic acid is applied directly to the cervix, allowing precancerous lesions to become visibly
white to the naked eye.11 This method has a greater margin for error and is not as accurate in
identifying the severity of the lesions. However, it requires little equipment and training to
perform.
When HPV was determined to be the cause of nearly all cervical cancers in the 1980’s, a
preventative vaccine as well as screening tools were developed. In 2007, the first prophylactic
vaccine for HPV became widely available.13 In the four years following introduction, HPV
infections in teen girls decreased by 56%.14 There are currently three options for vaccination,
each covering various high-risk strains (quadrivalent Gardasil/Silgard, bivalent Cervarix,
nonvalent Gardasil 9). All three vaccines cover high-risk strains 16 and 18, but none protect
against all HPV types.13 The CDC in the United States recommends routine vaccination at 11 or
12 years of age, as children ideally should be vaccinated before any exposure to the human
papillomairus.14 Both males and females should be vaccinated, as both genders can transmit the
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virus. Long-lasting immunity can be generated with 2-3 doses of the non-infectious recombinant
vaccine.15
The vaccine is a great option for those who are able to receive it before HPV exposure,
but it is not therapeutic. To identify the virus after contraction has occurred, patients can undergo
an HPV screening test. This detects the DNA of the virus itself, rather than the cellular changes
that cytology detects. HPV testing is highly sensitive and allows for longer screening intervals –
done every five years rather than three with cytology alone. A negative HPV test indicates the
patient is not infected with an HPV type that is linked to cervical cancer, whereas a positive test
indicates there is a presence of cancer-linked HPV.16 A positive test does not indicate the
presence of cancer, but instead identifies at risk patients. HPV testing can conveniently be
completed with the same sample obtained for cytologic testing. These tests are almost always
completed together, deemed “co-testing” to providers and patients. The combination of the test
results allows providers to gain a more complete understanding of HPV presence and disease
progression. If the two tests do not correspond, further testing with colposcopy may be indicated.
HPV tests also produce a large number of false positives, which may lead to unnecessary
testing.11
Prevention and screening methods are largely based on the peaks of acquisition at each
stage of the disease. For example, the peak age group that women contract the HPV virus is in
adolescence and early adulthood. The goal of the vaccination is to prevent infection before
exposure occurs. Because researchers have found that the vast majority of infections are cleared
naturally in young women, it is not recommended to screen with cytology until 21 years of age.16
With predictive progression, the peak of HSIL lesions has been found to be around 25-30 years
of age. In accordance with this data, it is advised that women are screened every three years with
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cytology from ages 21-29. From ages 30-65, women may be screened with an HPV co-test (Pap
+ HPV test).16 Because the HPV test is more sensitive to high-grade persistent lesions, it is not
recommended for women under 30 who are more likely to have a transient infection. Studies
have shown that the peak of cervical cancer in women is not until 45-60 years of age. This
highlights the large window of intervention time before a high-grade lesion advances to cancer.
Although these screening practices can be very effective, they are only useful if women
have the ability to access and afford follow-up visits and treatment. The WHO mentions that
successful programs are designed in order to reach the largest amount of women at risk with
quality screening and treatment.15
Prevention and Screening in Central America
Women in developing countries are disproportionately affected by cervical cancer. While
the incidence of cervical cancer has consistently decreased in many areas, the same cannot be
said for underdeveloped and low income nations. Technological advances that could allow
prevention of the disease are not available to a large number of women. In the years after the
invention of the HPV vaccine, only 3% of 10-20 year old females in less developed countries
had received a dose.17 Throughout Central America, the incidence and mortality rates of cervical
cancer vary considerably. In terms of cancer-related deaths, it is the leading cause in El Salvador,
and the sixth most in Costa Rica.18
In terms of prevention, there are some programs focused on administering HPV
vaccinations in some areas of Central America. In 2015, Panama was the only Central American
country with a national vaccination schedule in place. 19 Unfortunately, there are many challenges
that must be overcome before the vaccine can become widely available. The vaccine is
expensive, requires more than one dose, and implementation strategies are currently ineffective.
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Additionally, the vaccine does not help women who have already been infected with HPV or
who are beyond the recommended age range. This leaves many women in need of adequate
screening strategies rather than prevention.
Pap testing is the most common method of screening around the world, but it requires an
office visit every three years, trained providers, and microscopic analysis. Despite years of
attempts to implement cytologic testing across Central America, rates of cancer still remain high
in most areas.19 In well-equipped laboratories in developed countries, there is about 50%
sensitivity in detecting high-grade lesions cervical lesions. Comparatively, sensitivity ranges
between 22-42% in Central American countries, indicating that the majority of lesions are
missed.20 A large number of programs in Central America are underfunded, and frequently lose
patients to follow up. The few organized programs that do exist are located in major urban
centers, which are inaccessible to a large portion of the population. Furthermore, a pelvic exam is
required to collect specimens for Pap tests, and many people in this region are apprehensive due
to cultural reasons.20
As previously discussed, HPV testing allows for less frequent testing, and more accurate
screening. Costa Rica, the most politically stable and economically developed country in Central
America, was the first in the region to begin HPV testing. The Costa Rican Ministry of Health
conducted a large scale, long-term project called “The Guanacaste Project.” Women in this area
had the highest cervical cancer rates in the country. After introduction of a multimethod
screening effort including HPV testing, there was a 31% cancer incidence reduction. 21 Many
years later in 2011 the Nicaraguan government launched careHPV, which allows women the
option to self-collect vaginal samples for HPV testing. While not as sensitive as a provider
collected specimen, more than 80% of women agreed to the self-collected sample. In addition,
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this collection method had a higher sensitivity for lesions in comparison to cytologic testing.20
With the results of these studies, El Salvador, Guatemala, Honduras, and Nicaragua all began to
introduce HPV testing to their pre-existing cytology programs.
Another technique commonly used in low-resource settings is visual inspection by acetic
acid (VIA). As previously mentioned, this test is inexpensive and allows precancerous lesions to
become visibly white to the naked eye.11 Because of the nature of the test, results are
immediately available, preventing the need for many follow up visits. This method requires little
training, and few resources. It is much more widely accepted across communities, and still
produces 80% sensitivity and 92% specificity.22
At this point in time, thousands of women in underserved parts of Central America do not
have access to screening measures. There is a lack of organized programs and access to both
funds and resources. Lack of services results in women seeking care when the disease has
become invasive, and treatment options are either expensive or nonexistent.
Methods
The PubMed and Google Scholar databases were utilized to complete literature searches
related to cervical cancer screening and prevention across the world, and specifically in Central
America. PubMed search terms included: cervical cancer prevalence, cervical cancer prevention,
cervical cancer screening Central America, HPV vaccination, and HPV testing. Google Scholar
search terms included: WHO HPV recommendations, cervical cancer prevention, cervical cancer
screening Central America, HPV vaccination, and HPV testing.
In addition to online research, in-person interviews were conducted in Costa Rica to gain
additional understanding of the topic. Providers and locals were asked about screening and
prevention practices currently used, opinions and attitudes related to methods, and access to care
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(See Appendix A). Interviews were conducted in various locations in Costa Rica, including San
Jose, Boruca, and Longo Mai. It is important to note that interviews were completed with Costa
Rican locals alone. Information from other Central American countries was inquired about, and
was also extrapolated from online resources.
Discussion
Ideally, the most current and up-to-date technologies should be available to all patients
receiving healthcare. Unfortunately, there are many barriers to providing even the most basic
healthcare necessities to large groups of people. As aforementioned, research on the preventative
and screening methods of cervical cancer has increased dramatically in the last 50 years. Because
of the nature of the disease, it is essential that HPV infections and precancerous lesions are
identified and treated before they are allowed to progress to cancer. The WHO and the Pan
American Health Organization (PAHO) have determined the most effective strategies, and have
created guidelines for optimal practice. However, Central American societies do not always have
the means to execute them. It is important to take financial, geographical, and cultural matters
into account to determine the best methods in this part of the world.
In the developed world, the HPV vaccine is utilized for prevention, and screenings
include Pap and/or HPV testing, followed by potential colposcopy, biopsy, or excisional
procedures. Screening as a whole has been proven to reduce the incidence of cancer, decrease the
rates of progressive disease, and save lives. While these techniques have been proven successful,
they are expensive and require trained professionals, high-level equipment, and multiple clinic
visits.
Primary prevention with the HPV vaccine is uncommon in most Central American countries.
Although there are many explanations for low vaccination rates, a prominent issue is simply a
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lack of public awareness. In 2013, over 600 mothers were interviewed in Honduras, and while
nearly all of them had been educated about cervical cancer, only 13% had heard of the HPV
vaccination.24 Despite worldwide support for the vaccine, most health systems do not cover
vaccination, meaning many patients could not afford to purchase it. Additionally, multiple doses
are required, which demands multiple visits to a clinic.
Frequency of visits required is also a considerable obstacle when using Pap tests for
screening. Screening requirements state that women should be tested every three years, yet the
necessary equipment if often not available locally. When there are a lack of resources, less
women receive care. If Pap tests cannot reach populations at the highest risk of developing
cancer, such as those in rural areas, there is little chance of positive change. Countries able to
screen 50-70% of women with a Pap test every 3-5 years have death rates of 4 in 100,000
women, whereas countries with more than 70% coverage see less than 2 in 100,000 deaths per
year.23 Even when screening is completed, lack of training or education in clinicians commonly
results in inadequate samples or interpretation.
HPV DNA testing is one of the most accurate screening methods, but comes with
considerable financial cost. In comparison to Pap tests alone, HPV co-testing would be more
efficient than cytology alone in less developed countries. Co-testing can allow patients to
decrease the time interval between screenings to five years rather than three.
In interviews, both residents and medical providers in Costa Rica recognized cervical cancer
as a prevalent problem for women. Pap screening was the most commonly used diagnostic test
for providers in both urban and rural areas. Even in Boruca, a small rural community in Costa
Rica, there were informative infographics and notices for screening with pap tests (Figure 1). Pap
test frequency recommendations were consistent with the WHO recommendations in these
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communities. While screening was seen to be very prevalent across the country, preventative
HPV vaccinations were absent from the required schedules (Figure 2). In regards to more
advanced cancer care, it was stated that access to colposcopy and further treatment is not easily
accessible. Many patients do not receive care due to the geographical distance to these facilities.
Even without these measures widely available, death rates in Costa Rica remain
significantly lower than in other Central American countries such as El Salvador. The main
reason for Costa Rica’s comparative success is the funding available for universal healthcare. In
1974, Costa Rica implemented a social security program—the Caja Costarricense de Seguro
Social (CCSS or Caja)—with the medical services offered by the Ministry of Health. 25 The
single-payer model is funded by employers, employees, and the government. Using this method,
nearly 90% of the population has access to quality care. 25 Unfortunately, other Central American
countries do not have the financial stability to put such a program in motion. As a result, the
quality of healthcare and access for patients is inadequate.
In order to reduce the incidence and mortality rate of cervical cancer in all Central
American countries, there are options to assist with outreach and access. For example, in 2003
Dr. Sanjeev Arora created Extension for Community Healthcare Outcomes (ECHO®). It has
been implemented to improve cancer care by connecting providers in high resource areas with
providers in lower resource areas. It is a low cost intervention that allows healthcare
professionals to “telementor” in order to share knowledge, guidance, and feedback. 18 The project
has been introduced in twelve regions of Central and South America regarding cervical
dysplasia. In this way, healthcare providers can become confident and skilled to provide
screening cares in their own communities. Higher numbers of properly trained clinicians equates
to increased patient care throughout the country.
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In addition to the ECHO® educational outreach, there are training programs such as the
Central America Gynecologic Oncology Education Program (CONEP). Volunteer gynecologic
oncologists travel to Latin America to provide instruction on hands-on screening and treatment
methods.26 While these types of programs are invaluable, it is important to recognize the need for
consistency and follow up to ensure the continuity of education.
It is also important to address the cost of services. Patients living in low-income, rural
areas are extremely unlikely to seek care if it is unaffordable. Currently, PAHO and the Global
Alliance for Vaccines and Immunizations (GAVI) financially supports HPV vaccines at a
discounted price.23 With government or organizational assistance from programs in each
individual country, vaccines could be made affordable or free of cost to the general public. In
terms of administration, many countries have found success in school-based vaccination
programs. This would help to cover nearly all young girls, particularly rural girls who might not
otherwise have access to healthcare.
When considering access to secondary prevention measures, adult women also have
difficulty finding access to frequent care. It has been suggested that mobile HPV screening
programs could help bridge the gap in access to care, but this would require a great deal of
planning and support. It is unclear whether these programs would be able to employ enough
well-trained staff to make a difference. Some countries around the world have also attempted to
introduce HPV testing in the form of self-collection, aiming to decrease stigma and increase
participation. While this may be true, the testing itself is still a costly option. Furthermore, if
HPV testing is administered without cytology, 15% of invasive cancers can be missed. 23
Financial burden on both systems and patients is also a large concern for both systems
and patients. VIA is already commonly used in low-resource settings due to its low cost,
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simplicity, and acceptance. One study found that VIA costs $3,198 per case in comparison to
$36,802 with cytologic screening.27 Given the financial constraints of many Central American
countries, this method is likely a leading approach to decrease cervical cancer incidence.
Conclusion
Ultimately, cervical cancer is a preventable disease with many opportunities to diagnose
and treat lesions before malignancy occurs. In developed countries with ample resources,
prevention and screening programs have decreased rates of incidence and mortality by at least
50%.8 However, the majority of countries within Central America have ineffective screening
programs due to lack of infrastructure and healthcare resources. Therefore, cervical cancer is one
of the leading causes of death in women of Central America.
HPV vaccinations are not widely administered, but should be a priority for the prevention
of disease in young girls. In terms of access to care, HPV co-testing with cytology is the most
accurate method to screen for precancerous and cancerous lesions. However, there are financial
and geographic challenges in reaching large populations of women in Central America with this
method.
There are several strategies that could help to provide both prevention and screening
measures to the masses of people living in urban and rural Central America. Expanding
programs such as ECHO® and CONEP can aid in bridging the educational gap. If funding
assistance can be procured from various worldwide organizations, the HPV vaccine can be
administered at low costs. The vaccination should be targeted towards young girls prior to the
onset of sexual activity, ideally in a school-based program.
In order for these programs to succeed, national recognition from the Ministries of Health
and governing bodies in Central America are required. Partnerships with health systems across
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the globe in combination with new initiatives have the potential to increase HPV vaccination
rates, improve access to services, as well as the quality of screening and treatment.
Currently, the most effective method in screening for cervical cancer is HPV co-testing
with cytology. However, with the barriers in low-resource areas in Central America, the best
option is likely visual inspection by acetic acid (VIA). It is a cost effective, well-recognized
strategy that requires little training of the clinician. With time and assistance, Central America
will move towards HPV co-testing, but the central focus should be providing accurate screening
to as many women in Central America as possible. Early detection and intervention could save
countless lives.
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Appendices
Appendix A:
Interview Questions
1. Is the HPV vaccine available at this location?
2. Is the HPV vaccine commonly given?
3. Are there any methods currently in place at this location to screen for cervical cancer? If
so, what are they?
4. Do you find that the screening methods are effective?
5. What do you think is the biggest barrier to cancer screening?

Appendix B: Figures

Figure 1: Papanicolau test information displayed in a small clinic in rural Boruca, Costa Rica.
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Figure 2: Vaccination schedule displayed in a small clinic in rural Boruca, Costa Rica.
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